Lung Cancer
Conference Coverage
Upfront NGS testing of metastatic NSCLC saves money, time
NGS at the time of metastatic NSCLC diagnosis could save millions of dollars relative to more conservative testing strategies, and results become...
From the Journals
E-cigarette usage has changed
More adults are trying them, but fewer are using them regularly.
Conference Coverage
Delay of NSCLC surgery can lead to worse prognosis
SAN DIEGO – Clinical stages deteriorate week by week – even when timing guidelines are followed.
Conference Coverage
Nivolumab shows promise in early-stage resectable NSCLC
The majority of 20 patients with resectable NSCLC were alive and recurrence-free 1 year after surgery and nivolumab treatment.
News
New lung cancer screening guideline from CHEST
An update to CHEST's lung cancer screening guideline, Screening for Lung Cancer: CHEST Guideline and Expert Panel Report, has just been published...
From the Journals
EAGLES: Smoking cessation therapy did not up cardiovascular risk
The overall rate of major adverse cardiovascular events was less than 0.5% in a study of smokers who received one of three cessation therapies or...
From the Journals
Nivolumab helps some with advanced NSCLC reach 5-year mark
For 129 patients with previously treated advanced non-small cell lung cancer, the estimated 5-year overall survival rate was 16%.
News
FDA wants data on role of flavored tobacco products in youth initiation
“Youth consistently report product flavoring as a leading reason for using tobacco products,” FDA Commissioner Gottlieb noted.
From the Journals
Fruquintinib promising agent for advanced NSCLC
Median PFS was 3.8 months with fruquintinib versus 1.1 months with placebo in heavily pretreated patients with advanced NSCLC.